Background: Although reduced red blood cell (RBC) lifespan has been reported to be a
contributory factor to anemia in patients with end-stage chronic kidney disease (CKD), there …

While recombinant human erythropoietin (rHuEPO) is an effective therapy for anemia in
renal failure, most published studies concern benefits in relatively healthy hemodialysis …

Background Anaemia is a very common problem in patients with end-stage kidney disease
(ESKD) and the use of erythropoietin-stimulating agents (ESA) has revolutionised its …

This Spanish single-arm, multicenter, prospective clinical trial assessed the maintenance of
hemoglobin concentrations (Hb) between 10-13 g/dL with unit doses of darbepoetin alfa and …

Background. Darbepoetin alfa is a new recombinant erythropoietic protein with a 3‐fold
longer half‐life than recombinant human erythropoietin (rHuEpo). The optimal starting dose …

Although treating anemia of chronic kidney disease by erythropoiesis-stimulating agents
(ESA) may improve survival, most studies have examined associations between baseline …

The guideline committee of Japanese Society for Dialysis Therapy (JSDT), chaired by
Professor F. Gejyo of Niigata University, now publishes an original Japanese guideline …

The difficulty maintaining hemoglobin (Hgb) within the targets recommended by KDOQI is
widely recognized. While factors responsible for erythropoietin resistance have been widely …

Aims: Erythropoiesis-stimulating agents (ESAs) are recommended for managing renal
anemia. ALTERNATE is an observational study in European and Australian dialysis patients …

Background This study was conducted to evaluate the efficacy and safety of once-monthly
continuous erythropoietin receptor activator (CERA) for maintenance of stable haemoglobin …